Voltage-dependent calcium channels in chondrocytes: roles in health and disease

Csaba Matta^{1,2,*}, Róza Zákány², Ali Mobasher^{1,3,4}

¹*The D-BOARD European Consortium for Biomarker Discovery, Department of Veterinary Preclinical Sciences, School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom*

²*Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen H-4032, Hungary*

³*Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Arthritis Research UK Pain Centre, Medical Research Council and Arthritis Research UK Centre for Musculoskeletal Ageing Research, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom*

⁴*Center of Excellence in Genomic Medicine Research (CEGMR), King Fahd Medical Research Center (KFMRC), King AbdulAziz University, Jeddah, 21589, Kingdom of Saudi Arabia*

*Corresponding author. Tel: +44 1483 68 2398; Fax: +44 1483 68 6711; E-mail address:

c.matta@surrey.ac.uk

This version of the article is the one that has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as follows: Curr Rheumatol Rep. 2015 Jul;17(7):521. doi: 10.1007/s11926-015-0521-4.

Abstract

Chondrocytes, the single cell type in adult articular cartilage, have conventionally been considered to be non-excitabile cells. However, recent evidence suggests that their resting membrane potential (RMP) is less negative than that of excitable cells, and they are fully equipped with channels that control ion, water, and osmolyte movement across the chondrocyte membrane. Among calcium-specific ion channels, members of the voltage-dependent calcium channel (VDCC) family are expressed in chondrocytes where they are functionally active. L-type VDCC inhibitors such as nifedipine and verapamil have contributed to our understanding of the roles of these ion channels in chondrogenesis, chondrocyte signalling, and mechanotransduction. In this narrative review, we discuss published data indicating that VDCC function is vital for chondrocyte health, especially in regulating proliferation and maturation. We also highlight the fact that activation of VDCC function appears to accompany various inflammatory aspects of osteoarthritis (OA) and, based on *in vitro* data, the application of nifedipine and/or verapamil may be a promising approach for ameliorating OA severity. However, very few studies on clinical outcomes are available regarding the influence of calcium antagonists, which are used primarily for treating cardiovascular conditions in OA patients. This review is intended to stimulate further research on the chondrocyte ‘channelome’, contribute to the development of novel therapeutic strategies, and facilitate the retargeting and repositioning of existing pharmacological agents currently used for other co-morbidities for the treatment of OA.

Keywords: Osteoarthritis (OA); Joint inflammation; Cartilage, Chondrocyte; Voltage-dependent calcium channel; Calcium channel blockers; Nifedipine; Verapamil

Abbreviations

BCP	Basic calcium phosphate
DHT	Dihydrotestosterone
ECM	Extracellular matrix
ET	Endothelin
GAG	Glycosaminoglycan
IGF-1	Insulin-like growth factor-1
MMP	Matrix metalloproteinase
OA	Osteoarthritis
PDGF	Platelet-derived growth factor
PGE ₂	Prostaglandin E ₂
PKC	Protein kinase C
PLC	Phospholipase C
PTHrP	Parathyroid hormone related peptide
RMP	Resting membrane potential
SLRP	Small leucine-rich proteoglycans
TGF- β	Transforming growth factor β
VDCC	Voltage-dependent calcium channel

Introduction

A thin layer of hyaline articular cartilage covers the articulating bones in most load-bearing synovial joints in the human body, where it enables frictionless movement and provides protection for subchondral bone. Adult cartilage contains a single cell type, the chondrocyte, with the main function of maintaining the proper composition of the extracellular matrix (ECM), in which they are embedded. The ECM of hyaline cartilage primarily consists of a dense and cross-linked meshwork of fibrillar collagens (predominantly type II collagen) and other minor collagens (mainly type VI, IX, and XI) that are incorporated in the fibrillar collagen network, regulating fibril assembly, organization, and degradation. This matrix is packed with large aggregating proteoglycans (e.g., aggrecan) and their constituent glycosaminoglycans (GAGs; e.g., chondroitin sulphate, keratan sulphate, hyaluronan, etc.), which possess a net negative charge attracting counteracting cations and high quantities of osmotically obliged water (approx. 70% of the net weight of ECM) [1]. Small leucine-rich proteoglycans (SLRPs) such as decorin, biglycan, and fibromodulin are specialised ECM molecules that contain multiple repeats of a leucine-rich structural motif, flanked by cysteine residues. SLRPs also modify the deposition and arrangement of fibrillar collagen fibres in the ECM. They also interact with cells and soluble growth factors such as transforming growth factor β (TGF- β) that may affect the proliferation of chondrocytes in addition to modifying the composition of the ECM.

As a unique type of connective tissue, mature articular cartilage is avascular, aneural and alymphatic [2]. Chondrocytes are surrounded by a pericellular matrix and are situated in cavities called lacunae within the ECM, where they exist in a hypoxic micro-environment [3, 4] and control ECM turnover and homeostasis in response to mechanical loading [5] despite having a rather slow (mainly anaerobic) metabolism. Due to the fact that chondrocytes reside within the peculiar milieu of the ECM (which is acidic, hypertonic and hyperosmotic [6-8]),

and since their function and differentiation is strongly dependent on intracellular calcium homeostasis [9, 10], they deploy a whole range of ion channels to enable ion transport across the plasma membrane; the collection of ion channels is referred to as the chondrocyte ‘channelome’ [11]. Albeit generally considered to be non-excitabile cells, chondrocytes and chondroprogenitor cells have been reported to express various voltage-dependent potassium channels (K_v), ATP dependent potassium channels (K_{ATP}), large and small conductance calcium-activated potassium channels (BK and SK), transient receptor potential channels (primarily TRPV1 and TRPV4), purinergic receptors (both P2X and P2Y subfamily members), voltage gated and epithelial sodium channels, chloride channels, and also voltage-dependent calcium channels (VDCCs) [11-13].

Physiology and pharmacology of voltage-dependent calcium channels (VDCCs)

Under physiological conditions, Ca^{2+} concentration is several thousand times higher in the extracellular space than in the cytoplasm. Activation of VDCCs results in rapid elevation of intracellular Ca^{2+} levels and initiates various cellular responses. VDCCs are typically closed at resting membrane potentials and their opening requires depolarization. VDCCs, along with other structurally similar voltage-gated ion channels such as Na_v or K_v channels, are tetrameric cation channels with four transmembrane domains (I-IV) surrounding a selective central pore and typically consist of α_1 , $\alpha_2\delta$, β , and γ subunits. Although the main structural and topological features of VDCCs are largely conserved, their physiological and pharmacological properties can be very different. The α_1 subunit, besides forming the pore, also determines the type of the channel; to date, 10 different α_1 subunits have been isolated, which can be classified into the structurally and functionally related families of Ca_v1 , Ca_v2 , and Ca_v3 (see *Table 1*). The other ancillary subunits (four $\alpha_2\delta$, four β , and eight different γ subunits are known) modulate the functional properties of these ion channels. There are five different types of VDCCs; members

of the L-type (or “Long Lasting”) group of Ca^{2+} channels contain one of the $\text{Cav}1.1$, $\text{Cav}1.2$, $\text{Cav}1.3$, or $\text{Cav}1.4$ α_1 subunits; the N-type (“Neural”) contains $\text{Cav}2.1$; the P/Q-type (“Purkinje”) contains $\text{Cav}2.2$; the R-type (“Residual”) contains $\text{Cav}2.3$; and members of the T-type (“Transient”) group contain $\text{Cav}3.1$, $\text{Cav}3.2$, or $\text{Cav}3.3$ α_1 subunits (*Table 1*) [14, 15]. It is of note that the L, N, P/Q and R-type calcium channels are activated at high voltage (HVA), while T-type calcium channels are activated at negative resting membrane potential (RMP) values and are considered as members of the low voltage-activated (LVA) family [16].

Inhibitors such as nifedipine or small peptide toxins from certain spider, snail, or scorpion species have contributed to our understanding of the roles of these calcium channels in various models. VDCCs are targets of existing drugs for the treatment of various cardiovascular diseases and central nervous system disorders. Dihydropyridines, phenyl-alkylamines, benzodiazepines, and other small molecules are widely used potent L-type channel blockers. Nifedipine is a member of the dihydropyridine family of calcium channel blocking agents. Its mechanism of action is to inhibit calcium influx, thereby causing, for example, smooth muscle cell relaxation and consequent vasodilation. Therefore, nifedipine, along with other dihydropyridines such as amlodipine or nicardipine, is a potent and widely used anti-hypertensive drug [17]. The phenyl-alkylamine verapamil, another potent calcium antagonist, binds to a distinct site on the ion channel and is also widely used as an anti-hypertensive drug [18]. The L-type channels are sensitive to the neurotoxin calciseptine, in addition to the conventional blockers [16]. The main modulators of N-type calcium channels are ω -conotoxins; P/Q-type channels are selectively blocked by ω -agatoxins; and the peptide neurotoxin SNX-482 is a selective R-type calcium channel inhibitor. To date, no specific blockers for T-type Ca^{2+} channels have been identified [19].

VDCCs and the effects of nifedipine/verapamil on chondrocytes

Whilst the roles of VDCCs in excitable cells such as muscle, nerve, or endocrine cells are well established, they act in an even more complex way in non-excitable cells that involves regulating enzyme activity or gene expression [19]. Although there is now an accumulating body of data demonstrating the presence and function of VDCCs in chondrocytes, their specific roles in different models are still not entirely clear. We therefore provide a detailed overview of what has been published in the literature, including our own findings, concerning VDCCs and the effects of the most frequently applied inhibitors such as nifedipine and verapamil in differentiating and adult chondrocytes.

The first implication that VDCCs might be involved in early steps of chondrogenic differentiation was published in 1989 [20]. When nifedipine (40–100 $\mu\text{mol/kg}$) was administered to rabbits *per os* on day 16 of gestation, a range of digital defects developed in the foetuses, including reduction, total absence, or abnormal structure of the distal phalanx of the fourth digit on the hind paws. These defects were mainly brought about by disturbed chondrogenesis and osteogenesis. It must be added, however, that administration of a drug with a different mechanism of action and different targets (i.e., hydralazine that blocks voltage-gated potassium channels) resulted in the same outcome, indicating that the effect of nifedipine on digit formation in the foetuses was not specific. Indeed, decreased utero-placental blood flow caused by excessive hypotension, rather than a direct blockade of the voltage-dependent ion channel, was implicated as the most probable mechanism underlying the observed defects in a follow-up study [21]. No apparent disturbance of chondrogenesis was observed in embryonic chick limb bud-derived micromass cultures at concentrations of nifedipine below $3 \times 10^5 \mu\text{M}$.

Additional, more specifically targeted experiments were carried out subsequently to explore the role of VDCCs in chondrocytes. In bovine articular chondrocytes, administration of endothelin or platelet-derived growth factor (PDGF) evoked either non-oscillatory Ca^{2+} transients or oscillatory Ca^{2+} events during single cell Ca^{2+} recordings, depending on the

subpopulation of cells [22]. Ca^{2+} spiking was not altered in the presence of nifedipine; also, depolarization of chondrocytes by high concentrations of K^+ did not induce Ca^{2+} transients and the study concluded that VDCCs were not functional in these cells. In contrast, nifedipine (administered i.v. at 6 mg/kg/day twice daily) interfered with elongation of long bones *in vivo* in growing rabbits, affecting the epiphyseal growth plate and bone remodelling [23]. This observation was supported by *in vitro* data; treatment of mouse embryonic limb bud-derived micromass cultures with nifedipine or verapamil during the early stages of differentiation inhibited chondrogenesis, reflecting on an important role of L-type VDCCs during cartilage formation [24]. Furthermore, in high-density primary cultures of human articular chondrocytes, application of verapamil or nifedipine abrogated the stimulatory effect of prostaglandin E_2 (PGE_2) on IGFBP-3, a protein that regulates the bioactivity and bioavailability of insulin-like growth factor-1 (IGF-1), an important mediator of chondrocyte metabolism [25]. In a follow-up study, IGF-1, IGF-2 and insulin all increased cytosolic Ca^{2+} levels in cultured rabbit articular chondrocytes but through different mechanisms; Ca^{2+} influx mediated by L-type VDCCs was involved downstream of IGF-1 and insulin, since verapamil diminished these responses [26].

In contrast to earlier observations [23], a different study showed that chicken growth plate chondrocytes did not express functional L-type VDCCs; whilst administration of high concentrations of extracellular K^+ evoked large intracellular Ca^{2+} transients, nifedipine (or nitrendipine) was unable to block channel activity, even at 10 times higher concentrations than used normally (at 100 μM) [27]. Furthermore, lack of Ca^{2+} transients evoked by BAY K 8644, an agonist that triggers activation and prolonged opening of L-type channels, corroborated the above findings. Cd^{2+} , on the other hand, significantly blocked K^+ -evoked Ca^{2+} transients, indicating that these cells mainly express N-type VDCCs.

To further elucidate the role of L-type VDCCs in bovine articular chondrocytes, their involvement in mediating cartilage ECM gene induction and matrix metalloproteinase (MMP)

gene suppression by capacitatively coupled electric field (60 kHz; 20 mV/cm) was investigated [28]. Whilst electrical stimulation significantly upregulated aggrecan and collagen type II mRNA expression, and at the same time downregulated IL-1 β induced MMPs, these were completely eliminated by the L-type VDCC blocker verapamil. However, this study did not demonstrate downstream pathways that link Ca²⁺ influx through VDCCs to the regulation of matrix genes.

To put in context the role of L-type VDCCs, a hypothesis was elaborated to explain the role of these channels in dihydrotestosterone (DHT) signalling; showing that DHT regulates growth plate chondrocytes in a sex-specific manner [29]. Upon binding to its 7-TM domain-containing plasma membrane receptor, DHT was proposed to initiate the phospholipase C (PLC) signalling pathway leading to Ca²⁺ release from internal Ca²⁺ stores through activation of IP₃ signalling; furthermore, G $\beta\gamma$ subunits would induce Ca²⁺ influx through L-type VDCCs in resting zone growth plate chondrocytes derived from male rats. The increase in cytosolic Ca²⁺ levels, sourced from both Ca²⁺ release and influx, would eventually activate classic protein kinase C (PKC) isoenzymes, leading ultimately to chondrocyte differentiation.

VDCC inhibitors influence proliferation and resting membrane potential (RMP) in chondrocytes

Every living cell is characterised by RMP, the voltage across the plasma membrane, which is generated by the activities of different ion channels or transporters with specific ion selectivities and permeabilities. As discussed earlier, even though the chondrocyte is a non-excitable cell type, RMP acts as a key biophysical signal modulating important activities such as volume regulation, proliferation, and differentiation [30]. To identify what roles VDCCs may play in the regulation of chondrocyte proliferation and RMP, several studies have been conducted. The first work in this field revealed that, in high density porcine articular

chondrocyte cultures, verapamil stimulated ^3H -thymidine uptake both in control conditions and following treatment with IGF-1; the stimulatory effect on cell proliferation was accompanied by a reduced rate of ^{35}S -incorporation indicative of inhibited GAG secretory processes [31]. In contrast, nifedipine appears to have the opposite effect on chondrocyte proliferation; application of 10 μM nifedipine completely abolished the enhanced proliferation and differentiation of chicken sternum-derived chondrocytes cultured on 3D collagen scaffoldings triggered by cyclic mechanical load [32]. To address the apparent contradiction between these two results, further experiments were conducted. When the influence of a set of ion channel inhibitors was studied on the RMP and proliferation of human chondrocytes isolated from OA knee cartilage [33], verapamil reduced the RMP of chondrocytes by 18%; also suggested was that the ion channel modulators investigated in this study might influence chondrocyte cell proliferation. Subsequent work showed marked suppression of proliferation in human articular chondrocytes following longer incubation times with verapamil; however, it must be noted that verapamil treatment also caused pronounced cytotoxic effects in these cells [34].

To gather further information on the effects of verapamil on the proliferation rate of chondrocytes, the influence of verapamil on endochondral ossification using foetal rat metatarsal rudiments was studied [35]. Verapamil reduced growth of the rudiments and the number of hypertrophic chondrocytes, as well as proliferation, indicating that the function of L-type VDCCs is also required for the proliferation of epiphyseal growth plate chondrocytes. Our own results showing an almost complete lack of proliferating cells in embryonic chicken limb bud-derived micromass cultures treated with nifedipine are in complete agreement with these findings [36], indicating an important positive role for VDCCs in regulating the proliferation of differentiating chondrocytes. The effects of nifedipine and verapamil on chondrocytes are summarised in *Table 2*.

Subunit-specific expression of VDCC: α_1 subunits

In the first study to describe the subunit-specific expression of VDCCs, Cav1.2 L-type α_1 subunit expression was identified in rat tracheal cartilage using immunohistochemistry [37]. Later on, the presence of the α_1 subunit protein of VDCCs was confirmed using a non-specific pan α_1 -subunit antibody in mouse limb bud organ cultures, in which they co-localised with Na, K-ATPase and epithelial Na⁺ channels in putative mechanoreceptor complexes [38]. These initial results were verified by analysing subunit-specific expression of L- and T-type VDCCs during cartilage and bone formation in mice [39]. According to these observations, intense immunoreactive signals for Cav1.2 (L-type) and Cav3.2 subunits (T-type) were visible along the perichondrium and in the growth plate at embryonic stage E14.5. At later stages (E18.5), Cav1.2 and Cav3.2 immunopositivity could still be observed in chondrocytes in the hypertrophic zone. These findings were corroborated using the murine chondrogenic cell line ATDC5.

Our group examined α_1 subunit expression profiles in embryonic chicken limb bud-derived chondrifying micromass cultures and identified members of L-type (Cav1.2 and Cav1.3); R-type (Cav2.3); and T-type (Cav3.1, Cav3.2, and Cav3.3) VDCCs [36], in a good agreement with previously published data. Although the above studies showed the presence of functional α_1 subunits in mature or differentiating chondrocytes, Cav3.2 was the first α_1 subunit identified as essential for tracheal chondrogenesis in mice; in mice lacking Cav3.2 channels, Sox9 expression was attenuated, accompanied by disturbed tracheal cartilage formation [40].

Mechanical load is partly mediated by L-type VDCCs in chondrocytes

Mechanotransduction pathways in chondrocytes are still incompletely understood, but there is a growing body of evidence that stretch-sensitive ion channels are involved in the process. To elucidate the contribution of Ca²⁺ channels in chondrocyte mechanotransduction

pathways, 10 μ M nifedipine was applied during mechanical stimulation of a 3D chondrocyte culture system established from 17-day-old chicken sterna [32]. As mentioned previously, nifedipine completely abolished the enhanced proliferation and maturation of chondrocytes triggered by mechanical load, indicating that L-type Ca^{2+} channels play an important role in mechanosensation and mechanotransduction in chicken sternum-derived chondrocytes.

When cyclic mechanical strain (7% or 12% elongation by a computer-driven vacuum-operated unit) was applied on growth ring-derived chondrocytes obtained from ribs of four-week-old male rats [41], pre-incubation with nifedipine (at 10 μ M) for 1 h before the strain was applied completely eliminated the strain-induced upregulation of parathyroid hormone related peptide (PTHrP), an important mediator of endochondral bone formation. These results supported the crucial function of VDCCs in mechanotransduction pathways.

Continuing this line of research, another group analysed how ion channel inhibitors, most importantly nifedipine, influenced the effects of static and dynamic compression in 3D bovine articular cartilage explants [42]. They observed that inhibition of VDCCs by nifedipine affected total protein synthesis more prominently than GAG synthesis, and concluded that a rather complex signalling process, including ion channels, may regulate mechanical loading-induced GAG production. To further scrutinise the potential role of VDCCs during cyclic mechanical compression, the ion channel regulation of cell spreading and retraction was studied in bovine chondrocytes [43]. Although nifedipine did not interfere with cell spreading immediately following mechanical compression, it prevented retraction compared to untreated control cells 6 h after stimulation, suggesting the involvement of VDCCs in regulating transient changes in cell shape. These findings led the authors to hypothesize that L-type VDCCs and $\alpha 5 \beta 1$ integrin, together with its associated Src kinase, form mechanoreceptor complexes that are involved in mechanosensation and mechanotransduction. As described earlier, a similar

hypothesis has been proposed that $\beta 1$ integrins, VDCCs, and other ion channels form functional mechanoreceptor complexes in embryonic mouse limb bud chondrocytes [38].

VDCCs are required for chondrogenesis

During the complex process of chondrogenesis, Ca^{2+} signalling pathways play determining roles [9, 10]. In earlier studies, we detected rapid Ca^{2+} oscillations, in addition to long-term sustained changes in cytosolic Ca^{2+} levels, in chicken limb bud-derived chondrogenic micromass cultures [44]. As mentioned above, treatment of mouse embryonic limb bud-derived micromass cultures with nifedipine during the early stages of differentiation blocked chondrogenesis, implicating the role of L-type VDCCs during the process [24]. Our research group was the first to describe that differentiating chondrocytes in chicken micromass cultures express the α_1 subunits of L-, R- and T-type VDCCs at both mRNA and protein levels; in particular, we detected mRNA transcripts encoding Cav1.2 and Cav1.3; Cav2.3; as well as Cav3.1, Cav3.2, and Cav3.3 VDCCs in complete agreement with previously published data (see [39]). We also reported that the L-type VDCCs play important roles in generating Ca^{2+} influx for oscillations, as nifedipine (10 μM) disrupted the regular pattern of repetitive calcium transients. Furthermore, VDCC blockade abrogated chondrogenesis and almost completely inhibited cell proliferation [36]. These results indicate that by mediating Ca^{2+} dependent signalling pathways in chondroprogenitor cells, L-type VDCCs may play a very important role during the initial stages of chondrogenesis.

As mentioned before, the T-type Cav3.2 was the first VDCC shown to be indispensable for tracheal chondrogenesis both *in vivo* and *in vitro* [40]. These findings were substantiated by the fact that mice lacking Cav3.2 showed congenital tracheal stenosis; conversely, Cav3.2 over-expression in ATDC5 cells augmented chondrogenesis. Presumably Ca^{2+} influx through Cav3.2 would activate the calcineurin/NFAT pathway, and regulate Sox9 during tracheal

chondrogenesis. However, it is unclear why only tracheal ring cartilage, but not other types of cartilage (*e.g.*, articular cartilage), is affected in mice lacking functional Cav3.2; the authors suggested that Cav3.2 is predominantly expressed in tracheal cartilage but hardly detectable in the other cartilages. Since these assumptions would contradict previous observations by other groups (see [39], for example), further studies are required to clarify the specific role of VDCCs (and Cav3.2 in particular) in chondrogenesis.

VDCCs in the context of OA pathogenesis

OA, a debilitating, multifactorial degenerative joint disease, is a main cause of pain, disability, and loss of mobility among the elderly. OA is characterised by gradual degeneration of articular cartilage, synovial inflammation (synovitis), and alterations to the peri-articular and subchondral bone; therefore, OA can be regarded as a disease of the whole joint. The molecular pathogenesis of OA is still not fully understood, which poses limitations to the development of effective disease-modifying therapeutic approaches [45].

As an attempt to shed more light on the molecular and physiological background of OA pathogenesis, the effects of basic calcium phosphate (BCP) crystals, associated with a rare, destructive form of OA phenotype, were investigated on cytosolic Ca^{2+} levels and Ca^{2+} oscillations in bovine articular chondrocytes and cartilage explants [46]. Inorganic BCP crystals elevated intracellular Ca^{2+} concentrations, induced Ca^{2+} oscillations, and at the same time enhanced the rate of matrix degradation (*i.e.*, augmented GAG release, and upregulated mRNA expression of MMP-3, ADAMTS-4 and ADAMTS-5). Furthermore, functional L-type VDCCs were required for the calcium phosphate crystal-induced Ca^{2+} oscillations to take place, as treatment with verapamil (1 μM) prevented the crystal-induced rise in cytosolic Ca^{2+} concentration. It must be noted, however, that the crystal-induced GAG release, rather than the upregulated mRNA expression of MMP-3, ADAMTS-4 and ADAMTS-5, was associated with

the increased cytosolic Ca^{2+} levels. Therefore, these results imply that by blocking VDCC function the deleterious effects of inorganic crystal-induced Ca^{2+} signals could be inhibited and thus the associated OA progression and severity might also be reduced.

The above results corroborated previous *in vivo* data also indicating the involvement of VDCCs in OA. In these papers the effects of PD-0200347, an $\alpha_2\delta$ ligand of VDCCs that selectively blocks Ca^{2+} currents, were studied in the anterior cruciate ligament resection dog model of OA. PD-0200347 significantly reduced the progression of structural changes in cartilage by reducing MMP-13 and iNOS gene expression and inhibiting ERK1/2 activation *via* a Ras-independent but PKC α -dependent mechanism [47, 48]. Taken together, these results suggest that VDCC-related Ca^{2+} signalling may be an important pathway involved in the pathogenesis of OA and that selective modulation and targeting of VDCC function might be beneficial for treating OA.

In a recent paper, a drug repositioning strategy was deployed to screen for already approved drugs that induce FRZB expression (a soluble antagonist of Wnt signalling) and subsequently downregulate the Wnt/ β -catenin pathway in human OA chondrocytes [49]. Verapamil, but not other Ca^{2+} channel blockers, upregulated FRZB gene expression and also stimulated chondrogenic marker gene (ACAN, COL2A1, SOX9) transcript levels. At the same time, verapamil reduced MMP3 expression. Furthermore, intra-articular injection of verapamil halted OA progression and ameliorated cartilage damage in knee joints in a rat OA-model [49]. Verapamil also inhibited hyaluronan export from IL-1 β treated chondrocytes by blocking the ABC transporter MRP5, and prevented the loss of aggrecan in osteoarthritic rat knee joints [50, 51]. However, since the inhibitory concentrations of verapamil that would be effective on the MRP5 transporter can never be reached in the serum using therapeutic and orally administered drug doses, an alternative hypothesis was suggested; the recent discovery that concurrent K^+ efflux through Ca^{2+} activated K_{ir} channels are required for hyaluronan export through MRP5

[52] suggest that blocking VDCC function and subsequent Ca^{2+} influx may inhibit K^{+} efflux and, simultaneously, excessive hyaluronan export. This hypothesis has yet to be validated.

Clinical data on the effects of VDCC inhibitors in OA patients

Various types of VDCCs are located throughout the human body participating in a wide range of functions. L- and T-type VDCCs are integral parts of the cardiovascular system and their over-activation could manifest in hypertension or arrhythmias; thus, they are the preferred targets of currently marketed calcium channel antagonists. Amongst the less frequent adverse effects of these medications, joint pain or *arthralgia* has been reported, but the frequency ranging from 0.5% to 3% does not differ significantly from that for placebo [53]. However, there are few studies available on the clinical outcome of calcium antagonists in joint pain, and collectively the evidence currently available is not convincing.

There are some case reports on individual patients with hypertension who developed muscle and joint pain whilst taking antihypertensive medication (i.e., diltiazem hydrochloride, or amlodipine); on discontinuation of these drugs the muscle and joint symptoms were resolved [53, 54]. In a multicentre, randomized, double-blind clinical trial with a 10-week treatment period that compared the effects of controlled-onset extended release verapamil (314 mg/day) with a conventional, gastrointestinal nifedipine therapy (64 mg/day), arthralgia was more frequent in the nifedipine group (6%) than in the verapamil group (2%); and the difference was statistically significant ($p=0.048$) [55]. However, increased frequencies of joint pain have not been reported in other studies [56]. It must be noted however that (1) some of these cases are probably individual occurrences of joint pain caused by the medications; and (2) arthralgia is a broad term that refers to joint pain and does not necessarily imply pain that is directly evoked by OA. In the clinical papers discussed above, no direct evidence was collected regarding the specific cause and the mechanism for joint pain.

As discussed in the previous section, the severity of experimental OA may be ameliorated using a VDCC inhibitor that selectively blocks Ca^{2+} currents [48]. In a recently conducted survey using the standardised Lequesne questionnaire, the severity of OA in osteoarthritic patients receiving calcium antagonists for the treatment of cardiac arrhythmia was investigated. This study reports that long-term treatment with currently used medications such as Adalat[®] (active ingredient, nifedipine), Amlodipine[®] (amlodipine), Carmen[®] (lercanidipine), Nitrendipine[®] (nitrendipin), and Norvasc[®] (amlodipine) led to improvements of OA severity, at least based on subjective patient feedback and Lequesne scores, compared to control patients (who were not taking calcium antagonists) [57]. However, that study has major limitations that must be taken into account. Firstly, patients in this study received co-medication. Secondly, patients were not randomized for the study; there were notable differences in the demographics between the groups; and no power analysis was performed. Thirdly, a heterogeneous group of calcium antagonists was included in the study. Finally, there is no evidence that antihypertensive drugs actually ameliorated the symptoms of OA in these patients; it might also be the case that the subjective disease improvement experienced by patients could have been caused by the desensitizing effects of Ca^{2+} antagonists on synovial nerve endings.

Conclusions and future directions

As it is now evident from data published *in vitro* and *in vivo* and summarised above, VDCCs are clearly important modulators of various functional aspects of chondrocyte physiology in health and disease, as well as during primary and terminal chondrocyte differentiation during pre- and post-natal growth plate development (i.e., chondrogenesis and endochondral bone formation). However, it is also evident that there are controversies and unresolved questions regarding their specific roles in chondrocytes from different sources (both

in terms of species and tissues of origin) and developmental stages. Depending on the experimental conditions applied, high concentrations of L-type VDCC blockers exert moderate to severe adverse effects on various signalling pathways, proliferation, growth and differentiation potential of chondrocytes both *in vitro* and *in vivo*, according to the literature reviewed here. These effects on chondrocytes from various sources analysed in diverse experimental conditions are summarised in *Table 2*.

It must be noted, however, that some of the effects of the VDCC inhibitors, nifedipine or verapamil, on bone growth [23], or chondrogenic nodule formation in micromass cultures [24] could have been caused by non-specific effects of long-term exposure (more than 7 days) to supraphysiological concentrations (up to 100 μM) of the drug. Such concentrations may never be achieved *in vivo* via oral administration of nifedipine and verapamil. Although the half-maximal concentrations of L-type Ca^{2+} channel antagonists have been described in the range of 20 nM to 50 μM , these values vary considerably in different cell types [58]. Concentrations higher than 50 μM are likely to block other calcium entry pathways, or even non-specifically block Na^{+} and K^{+} channels; verapamil can also inhibit T-type channels even at intermediate concentrations [18, 58], or the ABC transporter MRP5 involved in hyaluronan export [51]. Given that the concentration of drug that actually reaches the chondrocyte within the articular cartilage of patients receiving medication for unrelated conditions (e.g., hypertension or arrhythmia) is as yet unknown, it is impossible to extrapolate from the *in vitro* data that is currently available.

Whilst the effects of VDCC blockage with supraphysiological concentrations of nifedipine and verapamil in healthy chondroblasts and chondrocytes are mostly deleterious as they include inhibition of proliferation, ECM synthesis, or chondrogenic differentiation, VDCCs and their inhibitors (mainly verapamil) appear to play contrasting roles in inflammatory OA chondrocytes. This may hold promise for the development of novel

therapeutic approaches, possibly even through drug retargeting approaches. However, the effects of verapamil on OA chondrocytes might also be attributable to other, non-specific targets of the drug, which need to be taken into account.

There are a few possible explanations for the observed differences in healthy and OA chondrocytes in terms of the effects of VDCC inhibitors and VDCC function. Firstly, healthy and OA chondrocytes have an altered complement of plasma membrane ion channels and porins, which can at least partially be attributed to ECM degradation during OA. In particular, a set of ion channels including Ca^{2+} activated potassium channels (BK and IK), Ca^{2+} activated Cl^- channels, aquaporin-1 (AQP1), as well as voltage-gated K^+ channels or the piezo-type mechanosensitive ion channel 2 (Piezo2) were differentially expressed in healthy *vs.* OA cartilage [59-61]. Most of these channels play important roles in setting the RMP. Some of them are also involved in chondrocyte volume regulation [62]. Secondly, as a consequence of altered ion channel expression and function, the RMP values in healthy and inflammatory OA chondrocytes are probably different. The RMP in freshly isolated canine (and also equine, ovine, and bovine) chondrocytes was much less negative compared to that of excitable cells [62]; this is of critical importance for the function of voltage-dependent Ca^{2+} channels – most importantly, T-type VDCCs. These channels are small-conductance, low voltage-activated channels [63], which may play a role in sustained Ca^{2+} entry in chondrocytes. It must be noted, however, that chondrocyte RMP values available in the literature may not reflect the actual “physiological” values because of inappropriately chosen experimental conditions - it is impossible to know if isolated and cultured chondrocytes will have the same RMP as chondrocytes *in situ*. Thirdly, based on the above, OA chondrocytes may be characterised by altered intracellular calcium homeostasis and linked Ca^{2+} dependent signalling pathways, adding a level of complexity to the picture. Clearly, future studies have to incorporate innovative experimental designs to address these possibilities.

As discussed earlier, our current understanding of VDCCs and the effects of the most widely used inhibitors in chondrocyte biology is limited and controversial, mainly because there are very few papers published in this specific area. It should also be added that studies showing no action of VDCC inhibitors in OA patients may have remained unpublished. To resolve the apparent contradictions, and to better understand the mechanism of VDCC function in different in healthy and OA chondrocytes, new basic and clinical studies should be conducted using physiologically and pharmacologically relevant concentrations of VDCC blockers with clearly defined endpoints, including a) a systematic and comprehensive analysis of VDCC subunit expression and function in various models; b) more representative *in vitro* models to enable a more specific identification of cellular and physiological targets of the inhibitors; and c) sensitive biomarkers that predict responses to the drugs [64, 65]. Besides providing a better understanding of chondrocyte biology in health and disease, these prospective studies may also lead to the development of novel approaches for improving articular cartilage bioengineering [66].

Paracelsus the ‘father’ of toxicology wrote: ‘*All things are poison and nothing (is) without poison; only the dose makes that a thing is no poison.*’ Clearly, it is the concentration that makes a drug toxic. Therefore, new preclinical and clinical studies to determine the therapeutic vs. deleterious doses of calcium-channel blockers such as nifedipine and verapamil are crucially needed.

Acknowledgements: C.M. is supported by the European Commission through a Marie Skłodowska-Curie Intra-European Fellowship for career development (project number: 625746; acronym: CHONDRION; FP7-PEOPLE-2013-IEF). A.M. is the co-ordinator of the D-BOARD Consortium funded by European Commission Framework 7 programme (EU FP7; HEALTH.2012.2.4.5-2, project number 305815, Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases). A.M. is also a member of the Arthritis Research UK Centre for Sport, Exercise, and Osteoarthritis, funded by Arthritis Research UK (Grant Reference: 20194). C.M and Z.R. are supported by a Research and Development grant from the Hungarian Government (project number: GOP-1.1.1-11-2012-0197). The authors are especially indebted to Dr Sita Bierma-Zeinstra, Professor of osteoarthritis and related disorders

at Erasmus Medical Centre in Rotterdam, The Netherlands for critical comments on the clinical aspects of this paper.

Conflict of interest statement: The authors wrote this paper within the scope of their academic and affiliated research positions. The authors declare no conflict of interests. The authors do not have any commercial relationships that could be construed as biased or inappropriate.

References

1. Iwamoto M, Ohta Y, Larmour C, Enomoto-Iwamoto M. Toward regeneration of articular cartilage. *Birth Defects Res C Embryo Today*. 2013;99(3):192-202.
2. Bora FW, Jr., Miller G. Joint physiology, cartilage metabolism, and the etiology of osteoarthritis. *Hand Clin*. 1987;3(3):325-36.
3. Pfander D, Gelse K. Hypoxia and osteoarthritis: how chondrocytes survive hypoxic environments. *Curr Opin Rheumatol*. 2007;19(5):457-62.
4. Rajpurohit R, Koch CJ, Tao Z, Teixeira CM, Shapiro IM. Adaptation of chondrocytes to low oxygen tension: relationship between hypoxia and cellular metabolism. *J Cell Physiol*. 1996;168(2):424-32.
5. Urban JP. The chondrocyte: a cell under pressure. *Br J Rheumatol*. 1994;33(10):901-8.
6. Guilak F, Erickson GR, Ting-Beall HP. The effects of osmotic stress on the viscoelastic and physical properties of articular chondrocytes. *Biophys J*. 2002;82(2):720-7.
7. Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. *J Cell Physiol*. 2010;222(1):23-32.
8. van der Windt AE, Haak E, Das RH, Kops N, Welting TJ, Caron MM, et al. Physiological tonicity improves human chondrogenic marker expression through nuclear factor of activated T-cells 5 in vitro. *Arthritis Res Ther*. 2010;12(3):R100.
9. Matta C, Fodor J, Szigyarto Z, Juhasz T, Gergely P, Csernoch L, et al. Cytosolic free Ca²⁺ concentration exhibits a characteristic temporal pattern during in vitro cartilage differentiation: a possible regulatory role of calcineurin in Ca-signalling of chondrogenic cells. *Cell Calcium*. 2008;44(3):310-23.
10. Matta C, Zakany R. Calcium signalling in chondrogenesis: implications for cartilage repair. *Front Biosci (Schol Ed)*. 2013;5:305-24.
11. Barrett-Jolley R, Lewis R, Fallman R, Mobasheri A. The emerging chondrocyte channelome. *Front Physiol*. 2010;1:135.
12. Fodor J, Matta C, Juhasz T, Olah T, Gonczi M, Szigyarto Z, et al. Ionotropic purinergic receptor P2X4 is involved in the regulation of chondrogenesis in chicken micromass cell cultures. *Cell Calcium*. 2009;45(5):421-30.
13. Matta C, Fodor J, Miosge N, Takacs R, Juhasz T, Rybaltovszki H, et al. Purinergic signalling is required for calcium oscillations in migratory chondrogenic progenitor cells. *Pflugers Arch*. 2015;467(2):429-42.
14. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. *Pharmacol Rev*. 2005;57(4):411-25.
15. Khosravani H, Zamponi GW. Voltage-gated calcium channels and idiopathic generalized epilepsies. *Physiol Rev*. 2006;86(3):941-66.

16. Pringos E, Vignes M, Martinez J, Rolland V. Peptide neurotoxins that affect voltage-gated calcium channels: a close-up on omega-agatoxins. *Toxins*. 2011;3(1):17-42.
17. van Geijn HP, Lenglet JE, Bolte AC. Nifedipine trials: effectiveness and safety aspects. *BJOG : an international journal of obstetrics and gynaecology*. 2005;112 Suppl 1:79-83.
18. Spedding M, Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. *Pharmacol Rev*. 1992;44(3):363-76.
19. Catterall WA. Voltage-gated calcium channels. *Cold Spring Harb Perspect Biol*. 2011;3(8):a003947.
20. Danielsson BR, Reiland S, Rundqvist E, Danielson M. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. *Teratology*. 1989;40(4):351-8.
21. Danielsson BR, Danielson M, Reiland S, Rundqvist E, Dencker L, Regard CG. Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators. *Teratology*. 1990;41(2):185-93.
22. Stojilkovic SS, Vukicevic S, Luyten FP. Calcium signaling in endothelin- and platelet-derived growth factor-stimulated chondrocytes. *J Bone Miner Res*. 1994;9(5):705-14.
23. Duriez J, Flautre B, Blary MC, Hardouin P. Effects of the calcium channel blocker nifedipine on epiphyseal growth plate and bone turnover: a study in rabbit. *Calcif Tissue Int*. 1993;52(2):120-4.
24. Zimmermann B, Lange K, Mertens P, Bernimoulin JP. Inhibition of chondrogenesis and endochondral mineralization in vitro by different calcium channel blockers. *Eur J Cell Biol*. 1994;63(1):114-21.
25. DiBattista JA, Dore S, Morin N, Aribat T. Prostaglandin E2 up-regulates insulin-like growth factor binding protein-3 expression and synthesis in human articular chondrocytes by a c-AMP-independent pathway: role of calcium and protein kinase A and C. *J Cell Biochem*. 1996;63(3):320-33.
26. Poiraudau S, Lieberherr M, Kergosie N, Corvol MT. Different mechanisms are involved in intracellular calcium increase by insulin-like growth factors 1 and 2 in articular chondrocytes: voltage-gated calcium channels, and/or phospholipase C coupled to a pertussis-sensitive G-protein. *J Cell Biochem*. 1997;64(3):414-22.
27. Zuscik MJ, Gunter TE, Puzas JE, Rosier RN. Characterization of voltage-sensitive calcium channels in growth plate chondrocytes. *Biochem Biophys Res Commun*. 1997;234(2):432-8.
28. Xu J, Wang W, Clark CC, Brighton CT. Signal transduction in electrically stimulated articular chondrocytes involves translocation of extracellular calcium through voltage-gated channels. *Osteoarthritis Cart*. 2009;17(3):397-405.
29. ElBaradie K, Wang Y, Boyan BD, Schwartz Z. Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes. *J Steroid Biochem Mol Biol*. 2012;132(1-2):15-23.
30. Yang M, Brackenbury WJ. Membrane potential and cancer progression. *Front Physiol*. 2013;4:185.
31. Taylor AM, Dandona P, Morrell DJ, Preece MA. Insulin like growth factor-I, protein kinase-C, calcium and cyclic AMP: partners in the regulation of chondrocyte mitogenesis and metabolism. *FEBS Lett*. 1988;236(1):33-8.
32. Wu QQ, Chen Q. Mechanoregulation of chondrocyte proliferation, maturation, and hypertrophy: ion-channel dependent transduction of matrix deformation signals. *Exp Cell Res*. 2000;256(2):383-91.
33. Wohlrab D, Wohlrab J, Reichel H, Hein W. Is the proliferation of human chondrocytes regulated by ionic channels? *J Orthop Sci*. 2001;6(2):155-9.

34. Wohlrab D, Vocke M, Klapperstuck T, Hein W. The influence of lidocaine and verapamil on the proliferation, CD44 expression and apoptosis behavior of human chondrocytes. *Int J Mol Med.* 2005;16(1):149-57.
35. Mancilla EE, Galindo M, Fertilio B, Herrera M, Salas K, Gatica H, et al. L-type calcium channels in growth plate chondrocytes participate in endochondral ossification. *J Cell Biochem.* 2007;101(2):389-98.
36. Fodor J, Matta C, Olah T, Juhasz T, Takacs R, Toth A, et al. Store-operated calcium entry and calcium influx via voltage-operated calcium channels regulate intracellular calcium oscillations in chondrogenic cells. *Cell Calcium.* 2013;54(1):1-16.
37. Wang XT, Nagaba S, Nagaba Y, Leung SW, Wang J, Qiu W, et al. Cardiac L-type calcium channel alpha 1-subunit is increased by cyclic adenosine monophosphate: messenger RNA and protein expression in intact bone. *J Bone Miner Res.* 2000;15(7):1275-85.
38. Shakibaei M, Mobasheri A. Beta1-integrins co-localize with Na, K-ATPase, epithelial sodium channels (ENaC) and voltage activated calcium channels (VACC) in mechanoreceptor complexes of mouse limb-bud chondrocytes. *Histol Histopathol.* 2003;18(2):343-51.
39. Shao Y, Alicknavitch M, Farach-Carson MC. Expression of voltage sensitive calcium channel (VSCC) L-type Cav1.2 (alpha1C) and T-type Cav3.2 (alpha1H) subunits during mouse bone development. *Dev Dyn.* 2005;234(1):54-62.
40. Lin SS, Tzeng BH, Lee KR, Smith RJ, Campbell KP, Chen CC. Cav3.2 T-type calcium channel is required for the NFAT-dependent Sox9 expression in tracheal cartilage. *Proc Natl Acad Sci U S A.* 2014;111(19):E1990-8.
41. Tanaka N, Ohno S, Honda K, Tanimoto K, Doi T, Ohno-Nakahara M, et al. Cyclic mechanical strain regulates the PTHrP expression in cultured chondrocytes via activation of the Ca²⁺ channel. *J Dent Res.* 2005;84(1):64-8.
42. Mouw JK, Imler SM, Levenston ME. Ion-channel regulation of chondrocyte matrix synthesis in 3D culture under static and dynamic compression. *Biomech Model Mechanobiol.* 2007;6(1-2):33-41.
43. Raizman I, De Croos JN, Pilliar R, Kandel RA. Calcium regulates cyclic compression-induced early changes in chondrocytes during in vitro cartilage tissue formation. *Cell Calcium.* 2010;48(4):232-42.
44. Varga Z, Juhasz T, Matta C, Fodor J, Katona E, Bartok A, et al. Switch of voltage-gated K⁺ channel expression in the plasma membrane of chondrogenic cells affects cytosolic Ca²⁺-oscillations and cartilage formation. *PloS One.* 2011;6(11):e27957.
45. Mobasheri A. The future of osteoarthritis therapeutics: targeted pharmacological therapy. *Curr Rheumatol Rep.* 2013;15(10):364.
46. Nguyen C, Lieberherr M, Bordat C, Velard F, Come D, Liote F, et al. Intracellular calcium oscillations in articular chondrocytes induced by basic calcium phosphate crystals lead to cartilage degradation. *Osteoarthritis Cart.* 2012;20(11):1399-408.
47. Boileau C, Martel-Pelletier J, Brunet J, Schrier D, Flory C, Boily M, et al. PD-0200347, an alpha2delta ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKCalpha dependent effect. *Ann Rheum Dis.* 2006;65(5):573-80.
48. Boileau C, Martel-Pelletier J, Brunet J, Tardif G, Schrier D, Flory C, et al. Oral treatment with PD-0200347, an alpha2delta ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. *Arthritis Rheum.* 2005;52(2):488-500.

49. Takamatsu A, Ohkawara B, Ito M, Masuda A, Sakai T, Ishiguro N, et al. Verapamil protects against cartilage degradation in osteoarthritis by inhibiting Wnt/beta-catenin signaling. *PloS One*. 2014;9(3):e92699.
50. Prehm P. Inhibitors of hyaluronan export prevent proteoglycan loss from osteoarthritic cartilage. *J Rheumatol*. 2005;32(4):690-6.
51. Schulz T, Schumacher U, Prehm P. Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. *J Biol Chem*. 2007;282(29):20999-1004.
52. Hagenfeld D, Borkenhagen B, Schulz T, Schillers H, Schumacher U, Prehm P. Hyaluronan export through plasma membranes depends on concurrent K⁺ efflux by K(ir) channels. *PloS One*. 2012;7(6):e39096.
53. Smith KM. Arthralgia associated with calcium-channel blockers. *Am J Health Syst Pharm*. 2000;57(1):55-7.
54. Phillips BB, Muller BA. Severe neuromuscular complications possibly associated with amlodipine. *Ann Pharmacother*. 1998;32(11):1165-7.
55. White WB, Black HR, Weber MA, Elliott WJ, Bryzinski B, Fakouhi TD. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. *Am J Cardiol*. 1998;81(4):424-31.
56. Snider ME, Nuzum DS, Veverka A. Long-acting nifedipine in the management of the hypertensive patient. *Vasc Health Risk Manag*. 2008;4(6):1249-57.
57. Daniilidis K, Georges P, Tibesku CO, Prehm P. Positive side effects of Ca antagonists for osteoarthritic joints - results of an in vivo pilot study. *J Orthop Surg Res*. 2015;10(1):1.
58. Hille B. *Ionic Channels of Excitable Membranes*. 2nd ed. Sunderland, Massachusetts, USA: Sinauer Associates, Inc.; 1992.
59. Gardiner MD, Vincent TL, Driscoll C, Burleigh A, Bou-Gharios G, Saklatvala J, et al. Transcriptional analysis of micro-dissected articular cartilage in post-traumatic murine osteoarthritis. *Osteoarthr Cart*. 2015;23(4):616-28.
60. Karlsson C, Dehne T, Lindahl A, Brittberg M, Pruss A, Sittinger M, et al. Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis. *Osteoarthr Cart*. 2010;18(4):581-92.
61. Lewis R, May H, Mobasheri A, Barrett-Jolley R. Chondrocyte channel transcriptomics: do microarray data fit with expression and functional data? *Channels*. 2013;7(6):459-67.
62. Lewis R, Asplin KE, Bruce G, Dart C, Mobasheri A, Barrett-Jolley R. The role of the membrane potential in chondrocyte volume regulation. *J Cell Physiol*. 2011;226(11):2979-86.
63. Jensen LJ, Holstein-Rathlou NH. Is there a role for T-type Ca²⁺ channels in regulation of vasomotor tone in mesenteric arterioles? *Can J Physiol Pharmacol*. 2009;87(1):8-20.
64. Hunter DJ, Nevitt M, Losina E, Kraus V. Biomarkers for osteoarthritis: current position and steps towards further validation. *Best Pract Res Clin Rheumatol*. 2014;28(1):61-71.
65. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyere O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: current status and perspectives. *Ann Rheum Dis*. 2013;72(11):1756-63.
66. Jahr H, Matta C, Mobasheri A. Physicochemical and biomechanical stimuli in cell-based articular cartilage repair. *Curr Rheumatol Rep*. 2015;17(3):493.

References to highlight as being:

• Of importance

•• Of major importance

- 14. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. *Pharmacol Rev.* 2005;57(4):411-25.

Comprehensive and authoritative review of the nomenclature, classification and structure-function relationships of voltage-dependant calcium channels.

- 20. Danielsson BR, Reiland S, Rundqvist E, Danielson M. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. *Teratology.* 1989;40(4):351-8.

The original study that highlighted defects in digit development induced by vasodilating agents.

- 32. Wu QQ, Chen Q. Mechanoregulation of chondrocyte proliferation, maturation, and hypertrophy: ion-channel dependent transduction of matrix deformation signals. *Exp Cell Res.* 2000;256(2):383-91.

One of the original studies that implicated calcium channels as stretch-activated entities involved in chondrocyte proliferation, maturation, and hypertrophy

- 47. Boileau C, Martel-Pelletier J, Brunet J, Schrier D, Flory C, Boily M, et al. PD-0200347, an $\alpha_2\delta$ ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKC α dependent effect. *Ann Rheum Dis.* 2006;65(5):573-80.

The first study to explore the in vivo effects of PD-0200347, an $\alpha_2(2)\delta$ ligand of voltage gated $\text{Ca}(2+)$ channels, on cell signalling in OA chondrocytes from an experimental dog model and examine the effects of this compound on the major signalling pathways involved in OA cartilage degradation.

- 53. Smith KM. Arthralgia associated with calcium-channel blockers. *Am J Health Syst Pharm.* 2000;57(1):55-7.

The first clinical study that reported on arthralgia associated with the use of calcium channel blockers.

- 57. Daniilidis K, Georges P, Tibesku CO, Prehm P. Positive side effects of Ca antagonists for osteoarthritic joints - results of an in vivo pilot study. *J Orthop Surg Res.* 2015;10(1):1.

Despite several important flaws in study design this paper is the first to report positive side-effects of calcium channel antagonists for treating OA.

- 64. Hunter DJ, Nevitt M, Losina E, Kraus V. Biomarkers for osteoarthritis: current position and steps towards further validation. *Best Pract Res Clin Rheumatol.* 2014;28(1):61-71.

The authors describe a fresh approach to biomarker validation and qualification for OA clinical trials that has recently commenced with the Foundation of NIH OA Biomarkers Consortium study. They discuss how biomarkers may support new drug development, preventive medicine, and medical diagnostics for osteoarthritis.

- 65. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyere O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: current status and perspectives. *Ann Rheum Dis.* 2013;72(11):1756-63.

This paper discusses the value of biomarkers in drug development for OA. In addition to being diagnostic and prognostic tools, biomarkers have utility as surrogate endpoints in clinical trials (efficacy of intervention).

Tables

Table 1. Classification of VDCCs based on their α_1 subunits and inhibitors.

Superfamily	Family	α_1 subunit	Gene	Pharmacology
High Voltage Activated	L	Cav1.1	CACNA1S	Dihydropyridines (nifedipine); phenyl-alkylamines (verapamil); calciseptine
		Cav1.2	CACNA1C	
		Cav1.3	CACNA1D	
		Cav1.4	CACNA1F	
	N	Cav2.1	CACNA1A	ω -conotoxins
Intermediate Voltage Activated	P/Q	Cav2.2	CACNA1B	ω -agatoxins
	R	Cav2.3	CACNA1E	SNX-482
Low Voltage Activated	T	Cav3.1	CACNA1G	No selective inhibitor discovered to date
		Cav3.2	CACNA1H	
		Cav3.3	CACNA1I	

Table 2. Effects of nifedipine and/or verapamil on chondrocytes at different developmental stages and under different experimental conditions.

	Effect(s) of Nifedipine and/or Verapamil	Experimental Conditions	Reference	Notes
1	Digital defects in rabbit foetuses	40–100µmol/kg nifedipine administered to rabbits <i>per os</i> on day 16	[20], [21]	Effects were attributed to decreased utero-placental blood flow.
2	No effect on Ca²⁺ signalling; high [K⁺] failed to evoke Ca²⁺ transients	Bovine articular chondrocytes	[22]	Nifedipine did not interfere with Ca²⁺ oscillations evoked by ET or PDGF.*
3	Influence epiphyseal growth plate and bone remodelling	6 mg/kg/day nifedipine administered IV twice daily to growing rabbits	[23]	
4	Nifedipine/verapamil inhibit chondrogenesis at early stages of differentiation	Mouse embryonic limb bud-derived micromass cultures	[24]	
5	Nifedipine/verapamil abrogate stimulatory effect of PGE ₂ on IGFBP-3	High density primary cultures of human articular chondrocytes	[25]	
6	IGF-1 and insulin evoke Ca ²⁺ influx through L-type VDCCs	Articular chondrocytes from 21-day-old rabbits; 1 µM verapamil	[26]	
7	Unable to block high K⁺ evoked Ca²⁺ transients	Chicken growth plate chondrocytes; nifedipine was used at 100 µM	[27]	BAY K 8644 had no effect; results indicate N-type channels.
8	Eliminate positive effects of capacitatively coupled electric field	Bovine articular chondrocytes; 40µM verapamil	[28]	
9	Prevents PKC activation downstream of DTH signalling	Male resting zone growth plate chondrocytes from rats; 10µM nifedipine	[29]	Ca ²⁺ release from internal stores was also involved in the pathway.
10	Verapamil stimulate ³ H-thymidine uptake and	High density porcine articular chondrocyte cultures; 40 or 80µg/mL verapamil	[31]	

11	Abolish enhanced proliferation rate caused by cyclic mechanical load	Chicken sternum-derived chondrocytes on 3D collagen scaffoldings; 10μM nifedipine	[32]	
12	Verapamil reduced RMP by 18% and suppressed proliferation	Human chondrocytes isolated from OA knee cartilage	[33], [34]	Longer incubation with verapamil was cytotoxic.
13	Influence on endochondral ossification and proliferation in foetal rat metatarsal rudiments	Rat epiphyseal growth plate chondrocytes; 10-100μM verapamil	[35]	
14	Disrupts regular pattern of calcium oscillations; abrogates chondrogenesis; almost completely blocks cell proliferation	Chicken embryonic limb bud-derived micromass cultures	[36]	
15	Completely eliminates the strain-induced upregulation of PTHrP	Cyclic mechanical strain on growth ring-derived chondrocytes from ribs of four-week-old male rats; 10 μM nifedipine	[41]	
16	Nifedipine more prominently affects protein synthesis compared to GAG synthesis	Static and dynamic compression in 3D bovine articular cartilage explants	[42]	
17	Prevents retraction after mechanical stimulation	Mechanical compression of bovine chondrocytes; nifedipine was used at 10 μM	[43]	Nifedipine did not interfere with cell spreading.

Note: Entries in **boldface** typesetting (lines 2 and 7) report negative results (i.e., implicate no function of VDCCs and/or their inhibitors)